MedTrace Logo

High-Dose Rosuvastatin Preloading for Enhanced Outcomes in STEMI Patients Undergoing Primary PCI

NCT06924684 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-04-11

No results posted yet for this study

Summary

To compare the efficacy of high dose rosuvastatin preloading vs placebo before primary PCI in terms of MACE at 30 days

Conditions

  • ST Elevation (STEMI) Myocardial Infarction

Interventions

DRUG

Statin monotherapy (rosuvastatin or atorvastatin)

Tab Rosuvastatin 40mg (weight) at presentation. Tab Rosuvastatin 20mg at night for 30 days.

DRUG

Placebo

Placebo caspule

Sponsors & Collaborators

  • Punjab Institute of Cardology

    collaborator OTHER

  • Sheikh Zayed Federal Postgraduate Medical Institute

    lead OTHER

Principal Investigators

  • Sohaib Ashraf, MD · Shaikh Zayed Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-02
Primary Completion
2025-06-23
Completion
2025-07-02

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06924684 on ClinicalTrials.gov